![shutterstock_663878965 [Converted]_natur](https://static.wixstatic.com/media/169631_ffbf004190a041c893ffb10fc7018166~mv2.png/v1/fill/w_132,h_84,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_663878965%20%5BConverted%5D_natur.png)
![shutterstock_663878965 [Converted]_natur](https://static.wixstatic.com/media/169631_ffbf004190a041c893ffb10fc7018166~mv2.png/v1/fill/w_124,h_80,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_663878965%20%5BConverted%5D_natur.png)
Innovative research treatment for cancer patients undergoing surgery for prevention
Cancer recurrence and prevention of cancer metastasis
The treatment is intended to prevent metastatic development, which may be accelerated around the time of surgery.
The treatment is based on existing and safe medications that are marketed in Israel and internationally, and which are given for a short period around the time of surgery.
This treatment reduces inflammatory responses and activity of the sympathetic nervous system and has been scientifically proven to be effective in animal and human studies.
The research is academic in collaboration with medical centers and Tel Aviv University, a non-profit organization and is not affiliated with pharmaceutical companies.
The treatment is provided free of charge and does not replace existing treatments.
Treatment begins 5 days before surgery and continues for about two weeks afterward.
A comprehensive explanation of our research
.jpeg)
.jpeg)
The research team
Prof. Shamgar Ben-Eliyahu
Prof. Shamgar Ben-Eliyahu heads the Neuroimmunology Research Laboratory at the School of Neuroscience at Tel Aviv University, and was previously head of the Department of Psychology. Prof. Ben-Eliyahu has been studying the relationship between surgery to remove a primary cancer tumor and the appearance of metastases and recurrence of the disease for two decades. Prof. Ben-Eliyahu is also developing drug treatments designed to reduce the impact of stress hormones and inflammation on the weakening of the immune system and the establishment and development of cancer metastases.
Prof. Oded Zamora
Prof. Oded Zmora is the director of the surgical department at Shamir Medical Center (formerly Assaf Harofeh Hospital). Prof. Zmora is a specialist in general surgery, colorectal surgery, which combines intestinal surgery, and proctology, which treats diseases of the rectum. Prof. Zmora is a graduate of the Hebrew University School of Medicine in Jerusalem. He completed his general surgery residency at Sheba Medical Center in Tel Hashomer and Mount Sinai Medical Center in New York. After completing his residency, Prof. Zmora specialized in colorectal surgery at the Cleveland Clinic in Florida, one of the world's leading centers in this field.
In addition to Prof. Ben Eliyahu and Prof. Zamora, doctors, nurses, and research coordinators at the hospitals participating in the study are taking part in this study
The scientific background to the research
We have developed a drug treatment based on existing, safe, and inexpensive drugs (Darlin and Etofen – or their generic names are propranolol and etodolac) that blocks the unwanted effects of inflammatory and stress factors. In animal studies, we have shown, in six different types of cancer, that drug treatment given around the time of surgery prevents metastases and saves lives after removal of the primary cancerous tumor. In humans, we have already conducted two small studies that have shown the safety of the treatment and promising results at the level of the cancer tissue and the prevention of bowel cancer recurrence after five years.
We are now testing the treatment on a large scale in several medical centers, with the goal of showing that it will prevent recurrence of metastases after surgery and save lives.
Journalism and scientific publications
מחקר ישראלי פורץ דרך:
תרופות קיימות וזולות
הצליחו למנוע משמעותית
חזרה של סרטן קטלני
2 common drugs may help protect against secondary cancer, small
Israeli study finds
8.12.22
Early study promising for
safe, cheap treatment
to prevent cancer
metastases
6.12.22
Israeli Scientists Find
Anxiety Medications Aid
Cancer Treatment
7.12.22
More flexible than previously thought: Worms give us new insights into the evolution and diversification of TGF-β signaling pathways
6.12.22
INVESTIGADORES ISRAELÍES
DESCUBRIERON TRES
FÁRMACOS COMUNES
QUE PUEDEN REDUCIR
EL RIESGO DE METÁSTASIS
TRAS UN CÁNCER
DE COLON O RECTO
7.12.22
불안, 염증 예방 약품 종양 수술 후 전이 위험 감소
7.12.22
Medicamentos para prevenir
la ansiedad, las reacciones
de estrés y la inflamación
reducen el riesgo de metástasis
después de la cirugía tumoral
6.12.22
出国看病资讯预防焦虑、应激反应和炎症的药物被发现可降低肿瘤手术后转移的风险
7.12.22
2 common drugs may
help protect against
secondary cancer,
small Israeli study finds
8.12.22
Des chercheurs israéliens
ont découvert trois médicaments
courants susceptibles
de réduire le risque
de métastases après un cancer
du côlon ou du rectum
8.12.22